Caitong International Asset Management Co. Ltd Has $544,000 Position in Regeneron Pharmaceuticals, Inc. $REGN

Caitong International Asset Management Co. Ltd raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 638.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 968 shares of the biopharmaceutical company’s stock after acquiring an additional 837 shares during the quarter. Regeneron Pharmaceuticals comprises 0.4% of Caitong International Asset Management Co. Ltd’s portfolio, making the stock its 29th largest position. Caitong International Asset Management Co. Ltd’s holdings in Regeneron Pharmaceuticals were worth $544,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of REGN. Salomon & Ludwin LLC bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at about $31,000. Caitlin John LLC bought a new stake in Regeneron Pharmaceuticals in the third quarter valued at about $34,000. Traub Capital Management LLC acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at about $38,000. Finally, Berbice Capital Management LLC lifted its stake in Regeneron Pharmaceuticals by 300.0% in the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 60 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 1,638 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the sale, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. The trade was a 49.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 46.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 5,274 shares of company stock valued at $4,142,738. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.3%

NASDAQ REGN opened at $759.05 on Wednesday. The firm has a market cap of $80.25 billion, a P/E ratio of 18.26, a P/E/G ratio of 2.03 and a beta of 0.41. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The stock’s 50-day moving average is $769.26 and its 200-day moving average is $698.18. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.Regeneron Pharmaceuticals’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period in the prior year, the business earned $12.07 EPS. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were given a dividend of $0.94 per share. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend was Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 9.05%.

Analyst Ratings Changes

REGN has been the subject of several analyst reports. Royal Bank Of Canada boosted their target price on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the stock a “sector perform” rating in a research report on Monday, March 2nd. Guggenheim lifted their price objective on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Barclays initiated coverage on shares of Regeneron Pharmaceuticals in a report on Friday, March 6th. They set an “overweight” rating and a $923.00 price objective for the company. BMO Capital Markets upped their target price on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a research note on Thursday, December 4th. Finally, Evercore increased their target price on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $802.27.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.